CLSN - Celsion Corporation ( NasdaqCM )

  • Ecco la 60° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.

    Questa settimana abbiamo assistito a nuovi record assoluti in Europa e a Wall Street. Il tutto, dopo una ottava che ha visto il susseguirsi di riunioni di banche centrali. Lunedì la Bank of Japan (BoJ) ha alzato i tassi per la prima volta dal 2007, mettendo fine all’era del costo del denaro negativo e al controllo della curva dei rendimenti. Mercoledì la Federal Reserve (Fed) ha confermato i tassi nel range 5,25%-5,50%, mentre i “dots”, le proiezioni dei funzionari sul costo del denaro, indicano sempre tre tagli nel corso del 2024. Il Fomc ha anche discusso in merito ad un possibile rallentamento del ritmo di riduzione del portafoglio titoli. Ieri la Bank of England (BoE) ha lasciato i tassi di interesse invariati al 5,25%. Per continuare a leggere visita il link

coffeman

Nuovo Utente
Registrato
14/6/04
Messaggi
29.905
Punti reazioni
1.192
occhio che ha brekkato e domani potrebbe fare il terzo soldato obiettivi in sequenza, stop se chiude sotto la linea rossa..
 

Allegati

  • CELSION CORP..png
    CELSION CORP..png
    15,1 KB · Visite: 1.775
direzione 2,8??;)
 
Conference call per il 15/03....e scende!!

Celsion Corporation to Hold Year-End 2011 Financial Results Conference Call on Thursday, March 15, 2012
LAWRENCEVILLE, NJ, Mar 08, 2012 (MARKETWIRE via COMTEX) -- Celsion Corporation /quotes/zigman/99941/quotes/nls/clsn CLSN -4.55% , a leading oncology drug development company, today announced that it would hold a conference call to discuss year-end 2011 results at 11:00 a.m. ET on Thursday, March 15, 2012. To participate in the call, interested parties may dial 1-888-359-3622 (Toll-Free/North America) or 1-719-325-2487 (International/Toll) and use Conference ID: 3234714 to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at Celsion Corporation - .

The call will be archived for replay on Thursday, March 15, 2012 at 2:00 p.m. ET and will remain available until Thursday, March 29, 2012. The replay can be accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517 (International/Toll) using Conference ID: 3234714. An audio replay of the call will also be available on the Company's website, Celsion Corporation - , for 30 days after 2:00 p.m. ET on Thursday, March 15, 2012.
 
e cosa vuol dire?
ci son state fugue di notizie negative sulla evento?
 
Celsion Reports First Quarter 2012 Financial Results
Company to Hold Conference Call on Tuesday, May 15th at 11:00 a.m. ET

LAWRENCEVILLE, NJ, May 15, 2012 (MARKETWIRE via COMTEX) -- Celsion Corporation /quotes/zigman/99941/quotes/nls/clsn CLSN -4.01% , a leading oncology drug development company, today announced financial results for the first quarter ended March 31, 2012 and provided a business update including development progress with ThermoDox(R), Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer. ThermoDox(R) is currently being evaluated under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA) in a global, multi-center, randomized, pivotal Phase III trial (the HEAT Study) in patients with non-resectable primary liver cancer. The HEAT Study has been designated as a Priority Trial for liver cancer by the National Institutes of Health, has received Fast Track Designation from the FDA and has received Orphan Drug Designation in both the U.S. and Europe. ThermoDox(R) is also being evaluated in two Phase II trials for patients with recurrent chest wall breast cancer and colorectal liver metastases.

"With the HEAT Study moving toward final data readout later this year, we have spent this first quarter focused on the realization of global enrollment objectives and preparing for a successful clinical and regulatory process to follow," said Michael Tardugno, Celsion's President and Chief Executive Officer. "Beyond the HEAT Study, we are strategically expanding our pipeline development efforts into additional areas of significant unmet need in which ThermoDox(R) may offer benefit. Since the beginning of 2012, we enrolled the first patient in our Phase II ABLATE Study of ThermoDox(R) in colorectal liver metastases, announced our support, in collaboration with the Focused Ultrasound Foundation, for preclinical studies evaluating ThermoDox(R) as an adjuvant to HIFU in pancreatic cancer and, together with Philips Heathcare, submitted an IND/IDE application for a Phase II study of ThermoDox(R) and HIFU in prostate metastases to the bone."

Recent Business Developments




-- In May, Celsion announced the signing of a long-term commercial supply
agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the China
territory. The agreement provides for Hisun funding of costs necessary
to complete the technology transfer of the Company's proprietary
manufacturing process and the production of registration batches for
the Chinese territory.


-- In May, following extensive evaluation of high intensity focused
ultrasound (HIFU) in bone cancer patients, Celsion announced the joint
resubmission with Philips Healthcare of a combined IND/IDE proposal
for a Phase II Study in prostate metastases to the bone, and the
Company's long term intent to pursue this important combination
therapy through multiple programs.


-- In May, the Company and the Focused Ultrasound Foundation announced
their support for preclinical studies designed to explore the use of
ThermoDox(R) in combination with MR-guided HIFU for the treatment
of pancreatic cancer. The studies are being conducted at the
University of Washington School of Medicine by Joo Ha Hwang, M.D.,
Ph.D., Director, Endoscopic Research, Associate Professor of Medicine
and Adjunct Professor of Bioengineering and Radiology.


-- In April, Celsion announced that the HEAT Study achieved its 200
patient enrollment target in the People's Republic of China (PRC), a
key milestone for the Company's global regulatory strategy as it
allows for regulatory filing in China -- a market which accounts for
over 50% of the 750,000 annual incidences of liver cancer.
Concurrently, Celsion announced that the HEAT Study's independent Data
Monitoring Committee (DMC) completed a safety review of 652 patients
and unanimously recommended that the study continue according to
protocol.


-- In February, Celsion announced that the first patient was enrolled in
a randomized Phase II study of ThermoDox(R) in combination with
radiofrequency ablation (RFA) for the treatment of colorectal liver
metastases (CRLM).







Financial Results

For the quarter ended March 31, 2012, Celsion reported a net loss of $6.2 million, or $0.19 per share, compared to a net loss of $3.7 million, or $0.28 per share, in the same period of 2011. In the first quarter of 2011, the Company recognized $2 million in licensing revenue as a result of its Development, Product Supply and Commercialization Agreement for ThermoDox(R) with Yakult Honsha Co. For the quarter ended March 31, 2012, net cash used in operations was $5.7 million.

Research and development costs increased by approximately $0.4 million to $4.7 million in the first quarter of 2012 compared to $4.3 million in the same period of 2011. These increased costs were primarily due to three ongoing clinical studies and activities related to the development of commercial manufacturing capabilities for ThermoDox(R). General and administrative expenses increased by approximately $0.4 million to $1.6 million, from $1.2 million for the same period in 2011. This increase is largely the result of an increase in professional fees and personnel costs to support the company's growth.

The Company ended the quarter with $24.6 million in cash and investments.

Quarterly Conference Call

The Company is hosting a conference call to provide a business update and discuss the first quarter 2012 results at 11:00 a.m. Eastern Time Tuesday, May 15, 2012. To participate in the call, interested parties may dial 1-877-741-4241 (Toll-Free/North America) or 1-719-325-4934 (International/Toll) and ask for the Celsion Corporation First Quarter 2012 Earnings Conference Call approximately ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at Celsion Corporation - .

The call will be archived for replay on May 15, 2012 at 2:00 p.m. ET and will remain available until May 22, 2012. The replay can be accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517 (International/Toll) using Conference ID: 3066549. An audio replay of the call will also be available on the Company's website, Celsion Corporation - , for 30 days after 2:00 p.m. ET Tuesday, May 15, 2012.

About ThermoDox(R) and the Phase III HEAT Study

ThermoDox(R) is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. In the HEAT Study, ThermoDox(R) is administered intravenously in combination with Radio Frequency Ablation (RFA). Localized mild hyperthermia (39.5 - 42 degrees Celsius) created by the RFA releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

For primary liver cancer, ThermoDox(R) is being evaluated in a global, multi-center, randomized, pivotal Phase III HEAT Study at 79 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox(R) in combination with RFA when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival with a secondary confirmatory endpoint of overall survival. Additional information on the Company's ThermoDox(R) clinical studies may be found at Home - ClinicalTrials.gov .

Credo che le attese erano migliori...
 
2❤12&More(Frattali,Frattaglie,Fritt ate,F ranchige,Franchi,Futures,Féssy)...

C L S N

chart
chart.ashx

big.chart

big.chart

occhio che ha brekkato e domani potrebbe fare il terzo soldato obiettivi in sequenza, stop se chiude sotto la linea rossa..
 
Roth Capital Starts Stock Coverage on Celsion (CLSN)
Posted by Latisha Jones on May 25th, 2012 // Read 0 Times // No Comment

Investment analysts at Roth Capital assumed coverage on shares of Celsion (NASDAQ: CLSN) in a note issued to investors on Thursday. The firm set a “buy” rating on the stock.

Shares of Celsion traded down 1.52% during mid-day trading on Thursday, hitting $1.94. Celsion has a one year low of $1.63 and a one year high of $4.37. The company’s market cap is $64.5 million.

Celsion Corporation (Celsion) is an oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer.

Forse è la volta buona che tocchiamo i 3$ ,,,,,,,,,,,,,,,,,,,,,,,
 
Occhio ragazzi, sembra che stia scaldando i motori, volumi non eccezionali ma buoni per il suo "carattere" e +5%, ultime news carine:cool::cool:
Qualcuno che sintetizzi l'analisi tecnica giornaliera?
 
quando sarà salita ci crederanno :D
 
Indietro